Development of the new antibiotics will receive funding through a public-private partnership.
For the initial period of 18 months, HHS will provide $40m and around $200m upon the renewal over five years.
GSK antibacterial discovery performance unit head David Payne said new models are required to deal with antibiotic resistance.
"We strongly believe that innovative public-private partnerships such as this are integral to solving this critical healthcare issue and we are delighted to work with BARDA in a more strategic way," Payne added.
The company can use the funding for its antibacterial portfolio, which facilitates the research towards potential treatment of both conventional and biothreat pathogens.
A BARDA-GSK joint oversight committee will monitor the progress and take decisions on fund allocation, while deciding on the addition or removal of the candidates from the portfolio.